Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease

de Bruyn, Magali; Machiels, Kathleen; Vandooren, Jennifer; Lemmens, Bart; Van Lommel, Leentje; Breynaert, Christine; Van der Goten, Jan; Staelens, Dominiek; Billiet, Thomas; De Hertogh, Gert; Ferrante, Marc; Van Assche, Gert; Vermeire, Severine; Opdenakker, Ghislain; Schuit, Frans; Rutgeerts, Paul; Arijs, Ingrid

doi:10.1097/01.MIB.0000438430.15553.90

Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease

Author:

de Bruyn, Magali

Machiels, Kathleen ; Vandooren, Jennifer ; Lemmens, Bart ; Van Lommel, Leentje ; Breynaert, Christine ; Van der Goten, Jan ; Staelens, Dominiek ; Billiet, Thomas ; De Hertogh, Gert ; Ferrante, Marc ; Van Assche, Gert ; Vermeire, Severine ; Opdenakker, Ghislain ; Schuit, Frans ; Rutgeerts, Paul ; Arijs, Ingrid

Keywords:

Science & Technology, Life Sciences & Biomedicine, Gastroenterology & Hepatology, inflammatory bowel disease, tissue remodeling genes, infliximab, mucosal expression, ULCERATIVE-COLITIS, CROHNS-DISEASE, AUTOIMMUNE-DISEASES, TISSUE INHIBITORS, METALLOPROTEINASES, ALPHA, BIOINFORMATICS, BIOMARKERS, PHENOTYPE, THERAPY, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, Biopsy, Dose-Response Relationship, Drug, Female, Gene Expression Regulation, Humans, Immunohistochemistry, Inflammatory Bowel Diseases, Infliximab, Intercellular Signaling Peptides and Proteins, Intestinal Mucosa, Male, Matrix Metalloproteinases, Middle Aged, Prospective Studies, RNA, Real-Time Polymerase Chain Reaction, Treatment Outcome, Tumor Necrosis Factor-alpha, Young Adult, 1103 Clinical Sciences, 3202 Clinical sciences

Abstract:

Matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), a disintegrin and metalloprotease with thrombospondin motifs [ADAM(TS)s] and growth factors are involved in inflammation and tissue damage and repair, all occurring in inflammatory bowel disease (IBD). We studied the impact of anti-inflammatory therapy with infliximab on mucosal expression of these tissue remodeling genes in patients with IBD.